Cervical cancer in the human papillomavirus vaccination era

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 1, 2012, Pages 3-7

  Tay, Sun Kuie ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

adenocarcinoma; Cervarix; cervical cancer screening; Gardasil; high grade abnormalities

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; AGE DISTRIBUTION; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; ETHNICITY; HEALTH CARE ACCESS; HUMAN; PRIORITY JOURNAL; REVIEW; RURAL AREA; URBAN AREA; URBAN RURAL DIFFERENCE; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AUSTRALIA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MASS VACCINATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84855772420     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32834daed9     Document Type: Review

References (48)

1. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19. (Pubitemid 29406813)
2. zur Hausen H. Viruses in human cancers. Science 1991;254:1167-1173. (Pubitemid 21917442)
3. Munger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63:4417-4421. (Pubitemid 19229441)
4. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 2007; 98:1505-1511. (Pubitemid 47308443)
5. Incassati A, Patel D, McCance DJ. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene 2006; 25:2444-2451.
6. De Sanjose S, Quint WC, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-1056.
7. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278. (Pubitemid 40590263)
8. Hernandez-Avila M, Wheeler CM, et al., The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-1943. (Pubitemid 46740303)
9. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
10. Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2,3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007; 369:1861-1868. (Pubitemid 46829356)
11. Paavonen J, Naup P, Salmeon J, et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-314.
12. Paavonen J, Jenkins D, Bosch X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with HPV types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. Lancet 2007; 369:2161-2170. (Pubitemid 46977438)
13. World Health Organization. WHO position on HPV vaccines. Vaccine 2009; 27:7236-7237.
14. Global Cancer Statistics (2011). http://www-dep.iarc.fr/. [Accessed 19 October 2011]
15. Homer MJ, Altekruse SF, Zou Z, et al. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev 2011; 20:591-599.
16. Singh GK. Rural-urban trends and patterns in cervical cancer mortality, incidence, stage, and survival in the United States, 1950-2008. J Community Health 2011. [Epub ahead of print]
17. Bastos J, Pelereiro B, Gouveia J, et al. The state of the art of cancer control in 30 European countries in 2008. Int J Cancer 2010; 126:2700-2715.
18. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002; 109:96-98.
19. Kale AR, Snape MD. Immunisation of adolescents in the UK. Arch Dis Child 2011; 96:492-495.
20. Smith LM, Brassard P, Kwong JC, et al. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health 2011; 11:645.
21. Brotherton JML, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-2092.
22. Fagot JP, Boutrelle A, Ricordeau P, et al. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011; 29:3610-3616.
23. Berry-Caban CS. HPV vaccination coverage among adolescents aged 9 to 17 years in a United States military treatment facility. Int J Adolesc Med Health 2009; 21:567-570.
24. Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 2011; 11:203.
25. Kane MA. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol 2010; 117:S32-S35.
26. Sue J, Goldie SJ, Diaz M, et al. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008; 26S:M17-M29.
27. Pettersson FB, Hellman K, Vaziri R, et al. Cervical cancer in the screening era: who fell victim in spite of successful screening program? J Gynecol Oncol 2011; 22:76-82.
28. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339:b2968.
29. Bay F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005; 14:2191-2199. (Pubitemid 41603267)
30. Gyllensten U, Lindell M, Gustafsson I, Wilander E. HPV test shows low sensitivity of Pap screening in older women. Lancet Oncol 2010; 11:509-510.
31. Cuzick J, Castañón A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102:933-939.
32. Rachel L, Winer RL, Kiviat NB, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-738. (Pubitemid 40271061)
33. Plummer M, Peto J, Franceschi S. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2011. [Epub ahead of print]
34. Ault K, Sings H, Bautista O, et al. Minimum serum antibody levels associated with protection from human papillomavirus 16 (HPV 16) reinfection among placebo subjects. J Clin Oncol 2005; 23:5024.
35. David MO, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115:S1-S6.
36. Olsson S-E, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5:696-704.
37. Castellsagué X, Muñ oz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105:28-37.
38. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study. Gynecol Oncol 2000; 78:97-105. (Pubitemid 30650338)
39. Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009; 125:525-529.
40. Wong C, Krashin J, Rue-Cover A, et al. Invasive and in situ cervical cancer reported to the Vaccine Adverse Event Reporting System (VAERS): first report on cases of high grade cervical lesions and invasive cervical cancer among vaccinated women outside clinical trials. J Womens Health 2010; 19:365-370.
41. Price RA, Koshiol J, Kobrin S, Tiro JA. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine 2011; 29:4238-4243.
42. Powell N, Boyde A, Tristram A, et al. The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: an observational retrospective analysis of invasive cervical cancers. Int J Cancer 2009; 125:2425-2427.
43. Lynge E, Antill A, Arbync M, et al. Whats next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 2009; 45:2714-2721.
44. Franco EL, Mahmud SM, Tota J, et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009; 40:478-485.
45. Creighton P, Lew JB, Clements M, et al. Cervical cancer screening in Australia: modeled evaluation of the impact of changing the recommended interval from two to three years. BMC Pub Health 2010, 10:734.
46. Bogaards JA, Coupe VMH, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011; 22:505-515.
47. Bingham A, Drake JK, LaMontagne DS. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009; 163:455-461.
48. Marek E, Dergez T, Kricskovic A, et al. Difficulties in the prevention of cervical cancer: adults attitudes towards HPV vaccination 3 years after introducing the vaccine in Hungary. Vaccine 2011; 29:5122-5129.